OCEANIC-STROKE: Asundexian Not Linked to More Major Bleeding
This secondary analysis of the OCEANIC-STROKE trial characterized bleeding outcomes in patients with noncardioembolic ischemic stroke or high-risk TIA who received asundexian plus antiplatelet therapy versus placebo. The trial reported no significant increase in major, major or clinically relevant nonmajor, or any bleeding with asundexian, with consistent treatment effects across prespecified subgroups; however, lower gastrointestinal bleeding, primarily rectal bleeding, was more frequent with asundexian (1.7% vs 1.0%).